Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
24677192
Public Release Type:
Journal
Publication Year: 2014
Affiliation: University of California, San Francisco, San Francisco, CA.
DOI:
https://doi.org/10.1002/hep.26920
Authors:
Doo E,
Terrault NA,
Stravitz RT,
Lok AS,
Everson GT,
Brown RS Jr,
Kulik LM,
Olthoff KM,
Saab S,
Adeyi O,
Argo CK,
Everhart JE,
Rodrigo del R,
A2ALL Study Group,
Emond JC,
Brown RS Jr,
Guarrera J,
Prince MR,
Samstein B,
Verna E,
Chawla T,
Heese S,
Lukose T,
Odeh-Ramadan R,
Zaretsky J,
Abecassis MM,
Baker T,
Kulik LM,
Ladner DP,
Al-Saden P,
Hong JC,
Busuttil RW,
Mooney J,
Freise CE,
Terrault NA,
MacLeod D,
Burton JR Jr,
Everson GT,
Kam I,
Trotter J,
Garcia C,
Krajec A,
Merion RM,
Akagi M,
Armstrong DR,
Brithinee A,
Hill-Callahan M,
Holloway L,
Howell TA,
Gillespie BW,
Golden B,
Lok AS,
Lowe M,
Ojo AO,
Shaw S,
Smith A,
Wolfe RA,
Hayashi PH,
Russell T,
Shaked A,
Olthoff KM,
Reddy K,
Rosen MA,
Conboy B,
Kaminski M,
McCorriston D,
Shaw M,
Berg CL,
Pruett TL,
Davis J,
Fisher RA,
Cotterell A,
Shiffman ML,
Stravitz R,
Ashworth A,
Davis J,
Fenick E,
Hofmann C,
Hubbard S,
Lassiter A,
Rodgers C,
Rodriguez J,
Wolfe L,
Everhart JE,
Hoofnagle JH,
James S,
Robuck PR,
Seeff LB,
Torrance RJ
Studies:
Adult Living Donor Liver Transplantation Studies
Donor factors influence hepatitis C virus (HCV) disease severity in liver transplant (LT) recipients. Living donors, because they are typically young and have short cold ischemic times, may be advantageous for HCV-infected patients. Among HCV-infected patients in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) surviving >90 days and followed for a median 4.7 years, advanced fibrosis (Ishak stage ≥3) and graft loss were determined. The 5-year cumulative risk of advanced fibrosis was 44% and 37% in living donor LT (LDLT) and deceased donor LT (DDLT) patients (P = 0.16), respectively. Aspartate aminotransferase (AST) activity at LT (hazard ratio [HR] = 1.38 for doubling of AST, P = 0.005) and biliary strictures (HR = 2.68, P = 0.0001) were associated with advanced fibrosis, but LDLT was not (HR = 1.11, 95% confidence interval [CI] 0.73-1.69, P = 0.63). The 5-year unadjusted patient and graft survival probabilities were 79% and 78% in LDLT, and 77% and 75% in DDLT (P = 0.43 and 0.32), with 27% and 20% of LDLT and DDLT graft losses due to HCV (P = 0.45). Biliary strictures (HR = 2.25, P = 0.0006), creatinine at LT (HR = 1.74 for doubling of creatinine, P = 0.0004), and AST at LT (HR = 1.36 for doubling of AST, P = 0.004) were associated with graft loss, but LDLT was not (HR = 0.76, 95% CI: 0.49-1.18, P = 0.23).
